EUVIMEDEUVIMED entdecken
Crossref

Suppression of B7-H7 Enhanced MCF-7 Cancer Cell Line’s Chemosensitivity to Paclitaxel

Bita Amir Taghavi, Mitra Salehi, Ahad Mokhtarzadeh, Behzad Baradaran

Molecular Biotechnology · 2025

DOI: 10.1007/s12033-024-01145-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biotechnology, 2025. Verfasst von Bita Amir Taghavi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran. Hauptthemen laut MEDLINE: Paclitaxel, B7 Antigens, Breast Neoplasms, Antineoplastic Agents, Phytogenic. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The B7-H7 is the newest addition to the B7 family of proteins that is present in the majority of malignancies. In this respect, the goal of the work was to investigate the impact of B7-H7 inhibition on breast cancer cells when paclitaxel and small interference RNA (siRNA) were combined. B7-H7 siRNA was used with Paclitaxel to treat MCF-7 cells. The IC50 of Paclitaxel and the cell survival was then assessed through using MTT assay. Investigation was conducted using flow cytometry to both the induction of apoptosis and the cell cycle. In addition, the clonogenic capacity of MCF-7 cells was investigated. Furthermore, qRT-PCR, was used to evaluate expression of genes. Our results demonstrated that suppressing B7-H7 sensitizes MCF-7 cells to Paclitaxel by triggering apoptosis and altering the expression of critical apoptosis mediator genes. In addition, the cell cycle was stopped in the sub-G1 and also G2-M phases as a result of the combination therapy leading prevention of developing colonies by MCF-7 cells. B7-H7 silencing improved the chemosensitivity of MCF-7 cells to Paclitaxel and demonstrated antiproliferative effects. After the adequate study has been conducted, this strategy may be regarded as a possible alternative treatment option for this cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelB7 AntigensBreast NeoplasmsAntineoplastic Agents, PhytogenicHumansMCF-7 CellsApoptosisRNA, Small InterferingFemaleCell CycleCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticDrug Resistance, Neoplasm

Stichwörter der Autor:innen

B7-H7Breast cancerCombination therapyImmune checkpointPaclitaxel

Substanzen

PaclitaxelRNA, Small InterferingB7 AntigensCD276 protein, humanAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Genetics, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran.
  • Immunology Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran.
  • Immunology Research Center, Tabriz University of Medical Sciences, Golgasht St., Tabriz, Iran. baradaranb@tbzmed.ac.ir.
  • Pharmaceutical Analysis Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. baradaranb@tbzmed.ac.ir.

Zitieren

APA

Taghavi, B. A., Salehi, M., Mokhtarzadeh, A., & Baradaran, B. (2025). Suppression of B7-H7 Enhanced MCF-7 Cancer Cell Line’s Chemosensitivity to Paclitaxel. Molecular Biotechnology. https://doi.org/10.1007/s12033-024-01145-2

Vancouver

Taghavi BA, Salehi M, Mokhtarzadeh A, Baradaran B. Suppression of B7-H7 Enhanced MCF-7 Cancer Cell Line’s Chemosensitivity to Paclitaxel. Molecular Biotechnology. 2025. doi:10.1007/s12033-024-01145-2

BibTeX
@article{Taghavi2025,
  author = {Taghavi, Bita Amir and Salehi, Mitra and Mokhtarzadeh, Ahad and Baradaran, Behzad},
  title = {Suppression of B7-H7 Enhanced MCF-7 Cancer Cell Line’s Chemosensitivity to Paclitaxel},
  journal = {Molecular Biotechnology},
  year = {2025},
  doi = {10.1007/s12033-024-01145-2}
}
Kostenlos starten →